[Form 4] Eli Lilly & Co. Insider Trading Activity
On 08/12/2025, Director J. Erik Fyrwald reported purchases of Eli Lilly & Co. (LLY) common stock totaling 1,565 shares across two transactions: 686 shares at a weighted average price of $641.996 and 879 shares at $642.586. The Form 4 shows beneficial ownership rising to 73,698.779 shares after the first purchase and to 74,577.779 shares after the second. The filing notes the reported prices are weighted averages across multiple executions within disclosed price ranges and offers to provide detailed per-price execution data on request.
Il 08/12/2025 il direttore J. Erik Fyrwald ha comunicato l'acquisto di azioni ordinarie di Eli Lilly & Co. (LLY) per un totale di 1.565 azioni in due operazioni: 686 azioni a un prezzo medio ponderato di $641.996 e 879 azioni a $642.586. La Form 4 indica che la partecipazione beneficiaria 猫 salita a 73.698,779 azioni dopo il primo acquisto e a 74.577,779 azioni dopo il secondo. La comunicazione precisa che i prezzi riportati sono medie ponderate di pi霉 esecuzioni entro le fasce di prezzo rese note e offre i dati dettagliati per singolo prezzo su richiesta.
El 08/12/2025, el director J. Erik Fyrwald inform贸 compras de acciones ordinarias de Eli Lilly & Co. (LLY) por un total de 1.565 acciones en dos operaciones: 686 acciones a un precio medio ponderado de $641.996 y 879 acciones a $642.586. El Form 4 muestra que la participaci贸n beneficiaria aument贸 a 73.698,779 acciones tras la primera compra y a 74.577,779 acciones tras la segunda. El documento se帽ala que los precios comunicados son promedios ponderados de varias ejecuciones dentro de los rangos de precio divulgados y ofrece facilitar los datos detallados por precio bajo petici贸n.
08/12/2025 鞚挫偓 J. Erik Fyrwald电� Eli Lilly & Co. (LLY) 氤错喌欤� 1,565欤�毳� 霊� 瓯挫潣 瓯半灅搿� 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟: 686欤�电� 臧�欷戫弶攴� 臧�瓴� $641.996鞐�, 879欤�电� $642.586鞐� 毵れ垬頄堨姷雼堧嫟. Form 4鞐惖鐢 觳� 氩堨Ц 毵れ垬 頉� 歆�攵勳澊 73,698.779欤�搿�, 霊� 氩堨Ц 頉勳棎电� 74,577.779欤�搿� 歃濌皜頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 鞝滌稖靹滊电� 氤搓碃霅� 臧�瓴╈澊 瓿奠嫓霅� 臧�瓴� 氩旍渼 雮挫棎靹� 鞐煬 觳搓舶鞚� 臧�欷戫弶攴犾瀯鞚� 氚濏瀳瓿� 鞛堨溂氅�, 鞖旍箔 鞁� 觳搓舶氤� 臧�瓴╈潣 靸侅劯 雿办澊韯半ゼ 鞝滉车頃橁矤雼り碃 鞝侅嫓頃橁碃 鞛堨姷雼堧嫟.
Le 08/12/2025, le directeur J. Erik Fyrwald a d茅clar茅 des achats d'actions ordinaires d'Eli Lilly & Co. (LLY) pour un total de 1 565 actions r茅parties en deux op茅rations聽: 686 actions 脿 un prix moyen pond茅r茅 de $641.996 et 879 actions 脿 $642.586. Le formulaire Form 4 indique que la d茅tention b茅n茅ficiaire est pass茅e 脿 73 698,779 actions apr猫s le premier achat et 脿 74 577,779 actions apr猫s le second. Le d茅p么t pr茅cise que les prix rapport茅s sont des moyennes pond茅r茅es de plusieurs ex茅cutions 脿 l'int茅rieur des fourchettes de prix divulgu茅es et propose de fournir, sur demande, les donn茅es d茅taill茅es par prix d'ex茅cution.
Am 08/12/2025 meldete Director J. Erik Fyrwald K盲ufe von Stammaktien der Eli Lilly & Co. (LLY) in H枚he von insgesamt 1.565 Aktien in zwei Transaktionen: 686 Aktien zu einem gewichteten Durchschnittspreis von $641.996 und 879 Aktien zu $642.586. Das Formular Form 4 weist einen Anstieg des wirtschaftlichen Eigentums auf 73.698,779 Aktien nach dem ersten Erwerb und auf 74.577,779 Aktien nach dem zweiten aus. Die Einreichung weist darauf hin, dass die gemeldeten Preise gewichtete Durchschnitte mehrerer Ausf眉hrungen innerhalb der offengelegten Preisbereiche sind und bietet auf Anfrage detaillierte Ausf眉hrungsdaten pro Preis an.
- None.
- None.
Insights
TL;DR: A director bought 1,565 LLY shares at roughly $642 each; size is modest relative to company scale.
The purchases total 1,565 shares executed on 08/12/2025 in two tranches at disclosed weighted average prices of $641.996 and $642.586. While director purchases can signal confidence, the absolute size (1,565 shares, roughly $1.0M at the reported prices) is small relative to Eli Lilly's market capitalization and does not by itself indicate a material change to ownership or control. The Form 4 properly discloses weighted-average pricing and offers to provide transaction-level details.
TL;DR: Disclosure is complete for Section 16 purposes; the transaction appears routine and non-material.
The Form 4 lists clear purchase codes and weighted-average prices and shows the reporting person as a Director. The statement that more granular execution data is available on request is consistent with transparency best practices. There are no indications of derivative transactions, option exercises, or changes in control. From a governance perspective this is a routine insider purchase disclosure with no material governance concerns disclosed in the document.
Il 08/12/2025 il direttore J. Erik Fyrwald ha comunicato l'acquisto di azioni ordinarie di Eli Lilly & Co. (LLY) per un totale di 1.565 azioni in due operazioni: 686 azioni a un prezzo medio ponderato di $641.996 e 879 azioni a $642.586. La Form 4 indica che la partecipazione beneficiaria 猫 salita a 73.698,779 azioni dopo il primo acquisto e a 74.577,779 azioni dopo il secondo. La comunicazione precisa che i prezzi riportati sono medie ponderate di pi霉 esecuzioni entro le fasce di prezzo rese note e offre i dati dettagliati per singolo prezzo su richiesta.
El 08/12/2025, el director J. Erik Fyrwald inform贸 compras de acciones ordinarias de Eli Lilly & Co. (LLY) por un total de 1.565 acciones en dos operaciones: 686 acciones a un precio medio ponderado de $641.996 y 879 acciones a $642.586. El Form 4 muestra que la participaci贸n beneficiaria aument贸 a 73.698,779 acciones tras la primera compra y a 74.577,779 acciones tras la segunda. El documento se帽ala que los precios comunicados son promedios ponderados de varias ejecuciones dentro de los rangos de precio divulgados y ofrece facilitar los datos detallados por precio bajo petici贸n.
08/12/2025 鞚挫偓 J. Erik Fyrwald电� Eli Lilly & Co. (LLY) 氤错喌欤� 1,565欤�毳� 霊� 瓯挫潣 瓯半灅搿� 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟: 686欤�电� 臧�欷戫弶攴� 臧�瓴� $641.996鞐�, 879欤�电� $642.586鞐� 毵れ垬頄堨姷雼堧嫟. Form 4鞐惖鐢 觳� 氩堨Ц 毵れ垬 頉� 歆�攵勳澊 73,698.779欤�搿�, 霊� 氩堨Ц 頉勳棎电� 74,577.779欤�搿� 歃濌皜頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 鞝滌稖靹滊电� 氤搓碃霅� 臧�瓴╈澊 瓿奠嫓霅� 臧�瓴� 氩旍渼 雮挫棎靹� 鞐煬 觳搓舶鞚� 臧�欷戫弶攴犾瀯鞚� 氚濏瀳瓿� 鞛堨溂氅�, 鞖旍箔 鞁� 觳搓舶氤� 臧�瓴╈潣 靸侅劯 雿办澊韯半ゼ 鞝滉车頃橁矤雼り碃 鞝侅嫓頃橁碃 鞛堨姷雼堧嫟.
Le 08/12/2025, le directeur J. Erik Fyrwald a d茅clar茅 des achats d'actions ordinaires d'Eli Lilly & Co. (LLY) pour un total de 1 565 actions r茅parties en deux op茅rations聽: 686 actions 脿 un prix moyen pond茅r茅 de $641.996 et 879 actions 脿 $642.586. Le formulaire Form 4 indique que la d茅tention b茅n茅ficiaire est pass茅e 脿 73 698,779 actions apr猫s le premier achat et 脿 74 577,779 actions apr猫s le second. Le d茅p么t pr茅cise que les prix rapport茅s sont des moyennes pond茅r茅es de plusieurs ex茅cutions 脿 l'int茅rieur des fourchettes de prix divulgu茅es et propose de fournir, sur demande, les donn茅es d茅taill茅es par prix d'ex茅cution.
Am 08/12/2025 meldete Director J. Erik Fyrwald K盲ufe von Stammaktien der Eli Lilly & Co. (LLY) in H枚he von insgesamt 1.565 Aktien in zwei Transaktionen: 686 Aktien zu einem gewichteten Durchschnittspreis von $641.996 und 879 Aktien zu $642.586. Das Formular Form 4 weist einen Anstieg des wirtschaftlichen Eigentums auf 73.698,779 Aktien nach dem ersten Erwerb und auf 74.577,779 Aktien nach dem zweiten aus. Die Einreichung weist darauf hin, dass die gemeldeten Preise gewichtete Durchschnitte mehrerer Ausf眉hrungen innerhalb der offengelegten Preisbereiche sind und bietet auf Anfrage detaillierte Ausf眉hrungsdaten pro Preis an.
FAQ
What transactions did J. Erik Fyrwald report on the LLY Form 4?
How did Fyrwald's beneficial ownership change after the reported transactions?
Are the reported prices exact transaction prices on the Form 4?
Did the filing report any derivative or option transactions?
Who signed or authorized the Form 4 filing on behalf of the reporting person?
